Navigation Links
PharmaMar Commences Clinical Trial in U.S. with New Antitumor Product, PM060184
Date:2/7/2011

MADRID, Feb. 7, 2011 /PRNewswire/ -- PharmaMar SA (Grupo Zeltia, ZEL.MC) has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

The trials will be performed in hospitals in the U.S., and also in France and Spain. The primary endpoints of this Phase I trial are to identify the dose limiting toxicity (DLT), the maximum tolerated dose (MTD) and the recommended dose (RD) of PM060184.

Additionally, the drug's pharmacokinetic profile will be defined and a preliminary evaluation of its antitumor activity in patients will be performed.

About PharmaMar

PharmaMar is Grupo Zeltia's biotechnology subsidiary; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis® is Spain's first antitumor drug. Yondelis® is currently approved for STS in 33 countries outside the EEA, and in 10 of those countries for platinum-sensitive ROC as well (including Brazil and Canada). Yondelis® is approved for STS and platinum-sensitive ROC in all 30 countries of the EEA; in Switzerland it is approved for STS. Phase II clinical trials with Yondelis® are also under way on prostate, breast, lung and pediatric cancers. PharmaMar has five other compounds in clinical development: Aplidin®, Irvalec®, Zalypsis®, PM01183 and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D program.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following
'/>"/>

SOURCE PharmaMar
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
2. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
3. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
4. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
7. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
8. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
9. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
10. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
11. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 3, 2015 According to ... Peripheral Vascular Devices Market (Embolic Protection, Chronic Total ... Grafts, IVC Filters, Stents, Balloons and Accessories) - ... Cardiology and Peripheral Vascular Devices Market is expected ... a CAGR of 7.4% from 2014 to 2019. ...
(Date:6/3/2015)... Conn. , June 3, 2015  SurgiQuest®, ... innovative access technologies for minimally invasive surgery (MIS) ... AirSeal® System in over 250,000 procedures.  Adoption has ... procedures over last year, driven by the company,s ... as well as geographic expansion to over 45 ...
(Date:6/3/2015)... PillPack, the pharmacy that simplifies medication management, today announced ... led by CRV with participation from Accel Partners, Atlas ... be used to fuel growth, accelerate the hiring of ... markets. "In the last two years, we,ve ... folks absolutely love," says TJ Parker, PharmD, CEO of ...
Breaking Medicine Technology:The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4Rapid Procedure Growth With SurgiQuest's AirSeal System 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 3
... 15, 2010 Menicon Co., Ltd. has announced its ... for Optimed,s CAPTIV8 communication services and i-Vue content-driven digital ... obtained exclusive distribution rights for Optimed,s products in Japan ... ) "First of all, I would like ...
... PRINCETON, N.J., Nov. 15, 2010 BioWa, Inc. announced ... with Agensys, Inc., an affiliate of Tokyo based Astellas ... ® Technology platform for the purpose of identifying ... "We are extremely pleased about our Agreement with ...
Cached Medicine Technology:Menicon Expands Partnership with Optimed in North America 2BioWa Announces License of POTELLIGENT® Technology to Agensys 2
(Date:6/3/2015)... Plano, Texas (PRWEB) June 03, 2015 ... Intelligence and Analytics solutions, today announced the launch ... Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio. ... embed additional visualization capabilities and advanced functionalities into ... of the DSX suite, Visual BI is adding ...
(Date:6/3/2015)... 03, 2015 Sitting at a computer ... in the back, neck, shoulders and/or wrists. This can ... In addition, recent research links sitting for long periods ... diseases. Fortunately, three inventors from Oakville, Ontario, are offering ... desk. , They have developed a prototype for a ...
(Date:6/3/2015)... GA (PRWEB) June 03, 2015 Fourroux ... in Duluth, GA will celebrate its grand opening with ... , The first prosthetic center of its kind in ... their family unmatched care and outcomes through use of ... Watson, CPO & CEO of Fourroux Prosthetics, states, “Our ...
(Date:6/3/2015)... TX (PRWEB) June 03, 2015 ... independent freestanding emergency rooms in the United States, announced ... Potranco facility in late June. , “I am ... in Texas with a new facility in the San ... Director of First Choice Emergency Room. , First ...
(Date:6/3/2015)... 03, 2015 Foot and Ankle ... Casey Friske ( Clarksville Division ) was recently ... Symposium of Advanced Wound Care (SAWC) and the American ... Dan Davis. The Conference was held on April ... Center in San Antonio, TX. , Dr. Casey ...
Breaking Medicine News(10 mins):Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2Health News:First Choice Emergency Room to Open New Facility in San Antonio, Texas 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Receives Award at the Spring 2015 Symposium of Advanced Wound Care Conference 2
... , SUNDAY, April 11 (HealthDay News) -- It,s easy to help ... according to the Alliance for a Healthier Generation. , For starters, ... active. And you can share the fun and health benefits, ... children to get on their bicycles, roller skates or blades and ...
... ... YHC magazine on April 25. , ... (Vocus) April 10, 2010 -- The Khanna institute to attend the YHC Health Expo ... CA 91361, , , , ,Khanna Institute of LASIK & Refractive surgery, an eye surgery ...
... ... York, announces the ten-year anniversary of his involvement with the Smiles for Life program. This ... directly to charities. , ... Lake, New York (Vocus) April 10, 2010 -- A dentist in a small community in ...
... ... send the equivalent of 10,000 laser targeted marketing postcards to all of your patient,s ... ... Traffic releases the easiest chiropractic marketing can be done right now in the ...
... ... presented by psychologist Paul G. Swingle, illustrates the use of neurotherapy in treating patients ... ADD, ADHD, epilepsy, stroke, learning disorders, traumatic brain injury, depression, fibromyalgia, and autistic spectrum ... ...
... ARBOR, Mich. Noting that the organization,s research "has touched ... nation," the National Cancer Institute (NCI) has renewed the Southwest ... funding package over that period expected to exceed $120 million. ... briefing by Group Executive Officer Anne F. Schott, M.D., and ...
Cached Medicine News:Health News:Khanna Institute of Vision and Your Health Connection Spring Expo 2Health News:Khanna Institute of Vision and Your Health Connection Spring Expo 3Health News:Ballston Lake Cosmetic Dentist Excited about 10th Year Participating in Smiles for Life Program 2Health News:Ballston Lake Cosmetic Dentist Excited about 10th Year Participating in Smiles for Life Program 3Health News:Chiropractic Traffic CEO Matt Prados Releases the Easiest and Fastest Free Chiropractic Marketing Method Known to Man 2Health News:Psychologist and Author Paul G. Swingle Talks about his Approach to Treating Depression and Mood Disorders in Online Forum 2Health News:Psychologist and Author Paul G. Swingle Talks about his Approach to Treating Depression and Mood Disorders in Online Forum 3Health News:SWOG cancer trials network awarded over $120 million in NCI grants 2
... protease secreted by the kidney, plays ... system. The renin-angiotensin system regulates blood ... retention by the kidney. Renin is ... including decreased intravascular volume and decreased ...
... polypeptide hormones which belong to the ... TGF- superfamily is a large group ... many aspects of development, reproductive function ... incude TGF-s, bone morphogenetic proteins, growth ...
... Human Insulin-like Growth Factor Binding Protein-1 ... the liver, which specifically binds and modulates ... The role of IGFBP-1 has not been ... regulation suggests that IGFBP-1 may be involved ...
... Human Insulin-like growth factor binding protein-2 ... (further IGFBPs have been proposed) which specifically ... and IGF-II. The binding affinity of IGFBP-2 ... higher than for IGF-I [1], suggesting a ...
Medicine Products: